홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
LIXT
#3813
Lixte Biotechnology Holdings, Inc. Common Stock
2.9
0
-2.68%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-2.68%
월간 변동
-15.20%
6달 변화
-15.20%
년간 변동율
+110.14%
이전 종가
2.9
8
Open
2.8
9
Bid
Ask
Low
2.8
5
High
2.9
4
양
20
마켓
주식
헬스케어
LIXT
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
2.25 M
2.68 M
2.68 M
4.56 M
5.7 M
—
Valuation ratios
Enterprise value
6.07 M
8.7 M
5.36 M
3.24 M
28.36 M
45.66 M
Price to earnings ratio
-1.12
-1.28
-0.83
-0.7
-4.26
-7.08
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-1.16
-1.44
-0.94
-0.82
-6.09
-9.3
Price to book ratio
-1.32
-1.71
-0.33
-0.32
-3.32
-5.68
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.58
-0.54
-0.47
-0.65
-0.36
-2.02
Return on equity %
-0.72
-0.75
-0.61
-1.19
-0.4
-2.95
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.13
1.12
4.26
1.84
10.42
17.65
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.43
-0.27
-0.23
-0.19
-0.24
-0.93
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.73
0.11
0.56
0.34
0.76
1.77
Net current asset value per share
0.75
0.16
0.61
0.38
1.43
2.58
Tangible book value per share
-0.95
-1.19
-0.95
0.25
0.62
-1.26
Working capital per share
0.6
0.02
0.47
0.17
1.29
1.95
Book value per share
-0.95
-1.19
-0.95
0.25
0.62
-1.26
뉴스
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary
LIXTE expands clinical trial for ovarian cancer treatment
스파르탄 캐피털, Lixte의 430만 달러 규모 유상증자 주선
Lixte Biotechnology stock falls after $4.3 million direct offering
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering
릭스테 바이오, 430만 달러 규모 직접 공모 후 주가 하락
Lixte Biotechnology stock falls after $4.3 million direct offering
Lixte Biotechnology raises $4.3 million in registered direct offering
Lixte Biotechnology, 주주총회서 이사 선임 및 주식 계획 수정안 승인
Lixte Biotechnology shareholders approve board nominees and stock plan amendment
Lixte Biotechnology, 영국 Liora 인수 후 주가 하락
Lixte Biotechnology stock falls after acquiring UK-based Liora